Sandoz, Inc. v. State
100 So. 3d 514
Ala.2012Background
- Sandoz, Inc. allegedly reported inflated generic-drug prices to DataBank, leading to Medicaid reimbursements claimed by the State to be excessive.
- AstraZeneca precedent governs, holding that reliance on allegedly inflated prices may be unreasonable where the State knew the prices were not net of discounts.
- AMA reimbursement methodologies (EAC, FUL, MAC) are federal/state-regulated and not solely determined by manufacturers’ price reports.
- Evidence showed WAC/AWP are not necessarily net prices; AMA knew or should have known this from DHHS correspondence and internal memoranda.
- State sought damages under fraud theories for misrepresentation and suppression, but the trial court issued a jury verdict in the State’s favor which the Supreme Court reversed and rendered for Sandoz.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Was there substantial evidence of fraud or suppression? | State argues Sandoz misrepresented prices to DataBank. | Sandoz contends State could not prove reliance or that prices were net. | No; State failed to show reasonable reliance and material misrepresentation. |
| Did the State reasonably rely on Sandoz’s price data? | State relied on DataBank prices to set reimbursements. | AMA policy decisions and federal directives dictated reimbursement, not Sandoz’s reports. | No; reliance was not reasonable given State’s own knowledge and independent policy decisions. |
| Did Government policy decisions nullify reliance on pricing data? | State argues the reimbursement formula was driven by its own studies. | AMA’s choices were policy-driven, not prompted by Sandoz’s price reports. | Yes; AMA policy decisions broke the causal chain of reliance. |
| Do FULs and MACs show lack of reliance on Sandoz’s prices? | State treated WAC/AWP as net prices for reimbursement. | FERMD/AMA relied on federal pricing controls (FUL/MAC) independent of Sandoz. | Yes; FULs and MACs demonstrate non-reliance on Sandoz’s reported prices. |
Key Cases Cited
- AstraZeneca LP v. State, 41 So.3d 15 (Ala. 2009) (central to whether State reasonably relied on reported prices and knowledge of non-net pricing)
- Hunt Petroleum Corp. v. State, 901 So.2d 1 (Ala. 2004) (reliance requires that misrepresentation induce change in conduct)
- Exxon Mobil Corp. v. Alabama Dep’t of Conservation & Natural Resources, 986 So.2d 1093 (Ala. 2007) (reliance analysis and whether to submit fraud issues to jury; sine qua non)
- AmerUs Life Ins. Co. v. Smith, 5 So.3d 1200 (Ala. 2008) (reasonable reliance standard in misrepresentation cases)
- Shades Ridge Holding Co. v. Cobbs, Allen & Hall Mortgage Co., 390 So.2d 601 (Ala. 1980) (requiring plaintiff to prove reliance was not merely conjectural)
- Baker v. Metropolitan Life Ins. Co., 907 So.2d 419 (Ala. 2005) (reliance and misrepresentation standards in Alabama)